Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 6, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 570,000 ordinary shares of 25 pence each.
- Purchase Price: 1,406.80 pence per share.
- Treasury Shares Held: 213,839,678 shares following the transaction.
- Shares in Issue: 5,774,621,894 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 570,000 shares on November 6, 2006, and intends to hold them in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the repurchase (570,000 shares at 1,406.80 pence) against the company's cash position in the most recent full financial report.
- Confirm the updated share count (5,774,621,894 in issue) for earnings per share calculations.
- Review the remaining authorization for share buybacks under the May 17, 2006 shareholder resolution.